Del Re M - Search Results

1

Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.

Rocco D, Malapelle U, Del Re M, Della Gravara L, Pepe F, Danesi R, Troncone G, Gridelli C. Rocco D, et al. Among authors: del re m. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):87-96. doi: 10.1080/17425255.2020.1721460. Epub 2020 Jan 30. Expert Opin Drug Metab Toxicol. 2020. PMID: 31978315 Review.

2

Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.

Di Paolo A, Bocci G, Polillo M, Del Re M, Di Desidero T, Lastella M, Danesi R. Di Paolo A, et al. Among authors: del re m. Curr Drug Metab. 2011 Dec;12(10):932-43. doi: 10.2174/138920011798062283. Curr Drug Metab. 2011. PMID: 21787264 Review.

3

Pharmacogenetics of anti-estrogen treatment of breast cancer.

Del Re M, Michelucci A, Simi P, Danesi R. Del Re M, et al. Cancer Treat Rev. 2012 Aug;38(5):442-50. doi: 10.1016/j.ctrv.2011.08.003. Epub 2011 Sep 13. Cancer Treat Rev. 2012. PMID: 21917382 Review.

4

Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.

Silvestris N, Del Re M, Azzariti A, Maiello E, Lombardi L, Cinieri S, Guarini A, Brunetti AE, Delcuratolo S, De Vita F, Pisconti S, Danesi R, Colucci G. Silvestris N, et al. Among authors: del re m. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S111-7. doi: 10.1517/14728222.2011.652089. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443211 Review.

5

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, Danesi R. Del Re M, et al. EPMA J. 2010 Sep;1(3):495-502. doi: 10.1007/s13167-010-0041-2. Epub 2010 Jul 25. EPMA J. 2010. PMID: 23199091 Free PMC article.

6

Author's reply: To PMID 22443211.

Silvestris N, Brunetti AE, Guarini A, Del Re M, Danesi R, Cinieri S. Silvestris N, et al. Among authors: del re m. Expert Opin Ther Targets. 2013 Apr;17(4):474-5. Expert Opin Ther Targets. 2013. PMID: 23610780 No abstract available.

7

Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.

Tomisti L, Del Re M, Bartalena L, Tanda ML, Pucci A, Pambianco F, Danesi R, Braverman LE, Martino E, Bogazzi F. Tomisti L, et al. Among authors: del re m. Endocr Pract. 2013 Nov-Dec;19(6):1043-9. doi: 10.4158/EP13093.RA. Endocr Pract. 2013. PMID: 23807523 Review.

8

DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.

Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. Terrazzino S, et al. Among authors: del re m. Pharmacogenomics. 2013 Aug;14(11):1255-72. doi: 10.2217/pgs.13.116. Pharmacogenomics. 2013. PMID: 23930673

9

Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.

Del Re M, Vasile E, Falcone A, Danesi R, Petrini I. Del Re M, et al. Expert Rev Mol Diagn. 2014 May;14(4):453-68. doi: 10.1586/14737159.2014.908120. Epub 2014 Apr 11. Expert Rev Mol Diagn. 2014. PMID: 24725257 Review.

10

Genetic variation: effect on prostate cancer.

Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R. Sissung TM, et al. Among authors: del re m. Biochim Biophys Acta. 2014 Dec;1846(2):446-56. doi: 10.1016/j.bbcan.2014.08.007. Epub 2014 Sep 6. Biochim Biophys Acta. 2014. PMID: 25199985 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page